

# Curriculum Vitae

## Personal information:

Name: Ahmad Anjomshoaa

Date of birth: 05/06/1972

Marital status: Married with two children

Tel: +98 9132990997

E-mail: anjomshoaa@kmu.ac.ir

## Qualifications

- Doctorate in Medicine (M.D), Kerman University of Medical Sciences, Faculty of Medicine, Kerman, Iran, 1997
- PhD in Medical Genetics, Cancer Genetics Laboratory, Biochemistry Department, Otago University, Dunedin, New Zealand, 2007

## Employment History & Administrative Positions

- Assistant Professor, Medical Genetics Department, Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran, April 2011-present
- Laboratory Director of Afzalipour Prenatal Diagnostic Center, Afzalipour University Hospital, Kerman University of Medical Sciences, Kerman, Iran, July 2013-present
- Laboratory Director of Diagnostic Genetics Department, Dabiri Private Medical Laboratory, Kerman, Iran, February 2023-Present
- Chief Executive Officer of Afzalipour University Hospital, Kerman University of Medical Sciences, Kerman, Iran, April 2022-December 2023
- Director of Clinical Laboratory Affairs, Deputy for Treatment, Kerman University of Medical Sciences, Kerman, Iran, July 2013-April 2022
- Head & Coordinator of Covid-19 Molecular Diagnostic Centers, Kerman University of Medical Sciences, Kerman, Iran, March 2020-April 2022
- Head and Laboratory Director of the Reference Laboratory, Deputy for Treatment, Kerman University of Medical Sciences, Kerman, Iran, July 2013-April 2022
- Laboratory Director of the Cancer & Immunogenetics Laboratory, Javad-Al Aemeh Medical Center, Kerman University of Medical Sciences, Kerman, Iran, May 2012-June 2024
- Genetic Counselor, Javad-Al Aemeh Medical Center, Kerman, Iran, 2012-present
- Head of Disaster Medical Assistance Team (DMAT), Kerman University of Medical Sciences, Kerman, Iran, 2015-2022
- Postdoctoral Fellowship, Cancer Genetics Laboratory, Biochemistry Department, Otago University, Dunedin, New Zealand, August 2008- March 2010
- Assistant Research Fellowship, Cancer Genetics Laboratory, Biochemistry Department, Otago University, Dunedin, New Zealand, August 2007- August 2008

- General Practitioner, Mashiz clinic, Kerman, Iran, 1998-2003

### **International Certificates & Training Courses and Hands-on Workshops**

- Certificate of Advanced Professional Training in the fields of Modern Technologies in the Medical Industry at the invitation of the Bavarian Ministry of Economic Affairs and Media, Energy and Technology, Munich, Germany, June 2017
- Advanced Clinical Cytogenetics Training Course, Diagnostic Genetics Department of LabPlus, Auckland City Hospital, Auckland, New Zealand, 2-16 June 2011
- Hands-on workshop on Preimplantation Genetic Diagnosis (PGD) of Genetic and Chromosomal Disorders by Blastocyst Biopsy, Istanbul Memorial ART & Reproductive Genetic Center, Istanbul, Turkey, May 2010
- Hands-on training courses on Affymetrix, Agilent and Roche NimbleGen Microarray Platforms, Otago Genomics Facility, Otago University, Dunedin, New Zealand, February 2010
- Several training courses and hands-on workshops in Advanced Cancer Cytogenetics including MLPA, FISH, SNP and aCGH techniques, Otago University, Dunedin, New Zealand, August 2007- March 2010

### **Professional Memberships**

- Membership of Iranian Neurogenetics Society, 2010-present
- New Zealand Society for Oncology, 2007-2010
- Membership of Iran Medical Council, 1998-present (membership ID number: 68632)
- Membership of Iran Genetics Council, 1998-present (membership ID number: A-2644)
- Member of population-based and hospital-based cancer registries, Kerman University of Medical Sciences, Kerman, Iran, August 2016-present
- Member of the University's Medical Equipment Committee, Kerman University of Medical Sciences, Kerman, Iran, December 2019-present

### **International Outstanding Achievements & Prizes and Awards**

- Patented invention of "A Gene Proliferation Prognostic Signature in Colorectal Cancer" with intellectual property number 562237, filed by Pacific Edge Biotechnology Ltd (PEL), Dunedin, New Zealand, October 2007
- Exceptional PhD thesis in the Division of Health Sciences, Biochemistry Department, Otago University, Dunedin, New Zealand, 2007
- The winner of Pfizer speaker award, NZ Society for Oncology Conference, Otago University, Dunedin, New Zealand, 9-11 May 2007

- Biochemistry Departmental Award (\$12,000), Otago University, Dunedin, New Zealand, April 2007
- Poster prize winner in the 5th Australian Microarray Conference, Adelaide, Australia, 29 September–1 October 2005
- Scholarship granted by Iran Ministry of Health and Medical Education for a PhD in Medical Genetics, 1999
- The winner of the second runner-up title of medical school graduates, Kerman University of Medical Sciences, Faculty of Medicine, Kerman, Iran, 1998
- Ranked 23 in national universities' entrance exam

### **International Presentations**

- Invited speaker for “Iran Neurogenetics Society Conference”, Kerman University of Medical Sciences, Kerman, 27-28 February 2025
- Invited speaker for “Pediatric dermatoses” Seminar, Kerman University of Medical Sciences, Kerman, 14 February 2025
- Invited speaker for “the 1<sup>st</sup>. International Pharmacogenetics Congress: Personalized Medicine”, Razi International Conference Center, Tehran, 6-8 November 2024
- Presenting a speech titled “Kerman University of Medical Sciences, Long History in Research, Teaching and Patient Care” for Health Research Committee Members of the Faculty of Medicine of Ludwig-Maximilians University, Munich, Germany, 22 June 2017
- Invited speaker to Genome Institute of Singapore, Singapore, 20-24 August, 2007
- The Opening speaker in World Congress on Gastrointestinal Cancer, Barcelona, Spain, 27-30 June 2007
- Invited speaker for New Zealand Society for Oncology Conference, Dunedin, New Zealand, 9-11 May 2007
- Invited speaker for the 183<sup>th</sup> Scientific Meeting of the Otago Medical School Research Society, Dunedin, New Zealand, May 2006
- Invited speaker for Genomic Facility Microarray Meeting, Dunedin, New Zealand, July 2005
- Poster presenter at the 5th Australian Microarray Conference, Adelaide, Australia, 29 September–1 October 2005

### **Related Publications**

1. Anjomshoaa A, Enhesari A, Dabiri S, Hoseinzadeh Mehrabi M, Shokrian J. A Stepwise, Prevalence-Driven Framework to Resolve Prenatal Testing Discrepancies: Integrating Institutional Expertise and a  $\beta$ -Thalassemia Case Study. Submitted to *BMC Pregnancy and Childbirth Journal*. At the peer review process

2. Azodian Ghajar H, Mansoori Y, Dastsooz H, Mashhadi R, Mirzaei A, Guitynavard F, Aghamir MK and Anjomshoaa A. Experimental and Bioinformatic Clues to the Potential Roles of CERS6-AS1 Long Non-Coding RNA in the Clinicopathology of Bladder Transitional Cell Carcinoma: An Exploratory Study. Submitted to *Helyion Journal*. Submitted responses to the reviewers' comments
3. Anjomshoaa A, Pourbagher H, Hoseinzadeh Mehrabi M, Shokrian J. Uninformative Restriction Fragment Length polymorphism sites as potential indicator of deletions in Beta-globin gene cluster in prenatal diagnosis of the beta thalassemia. Submitted to *Hemoglobin Journal*. Editor reviewing stage
4. Mehta S, Wright D, Black MA, Merrie A, Anjomshoaa A, Munro F, Reeve A, McCall J, Print C. Impact of Clinical Data Veracity on Cancer Genomic Research. *JNCI Cancer Spectrum* 2022; **6**(6): pkac070
5. Miri Karam Z , Baba Salari M, Anjom Shooa A, Dehghan Kouhestani S, Bahram Nejad S, Ashourzadeh S , Zangouyee MR, Bazrafshani MR. Impact of oxidative stress SNPs on sperm DNA damage and male infertility in a south-east Iranian population. *Reprod Fertil Dev* 2022;**34**(8):633-643
6. Ebrahimi Meimand HA, Iranmanesh F, Nasiri A, Anjomshoa A, Khosravimashizi A, Jafarzadeh A. Lamotrigine-related skin side effects were associated with some HLA-B alleles in Iranian epileptic patients. *JKMU* 2021;**28**(6): 71-78. doi: 10.22062/jkmu.2022.91865
7. Hosseninasab A, Shafiei Bafti M, Ebrahimi S, Anjomshoaa A, Sadeghi Zerandi F, Jafari M, Eslami S, Khalooei A. Coronavirus Disease 2019 in Children with Acute Respiratory Infection: A Study from Southeastern Iran. *Shiraz-E Medical Journal* 2020; **21**: 12
8. Nasri S, Humar B, Anjomshoaa A, Moradi N, Gholipour N, Mashjoor S, Zhang P. Early Hereditary Diffuse Gastric Cancer (eHDGC) is Characterized by Subtle Genomic Instability and Active DNA Damage Response. *Pathology & Oncology Research* 2019; **25**:711–721
9. *Kemp RA, Black MA, McCall J, Yoon H-S, Phillips V, Anjomshoaa A and Reeve AR.* T cell subpopulations in lymph nodes may not be predictive of patient outcome in colorectal cancer. *Journal of Experimental & Clinical Cancer Research* 2011; **30**:78
10. Nasri S, Anjomshoaa A, Song S, Guilford P, McNoe L, Black MA, Philips V, Reeve AR, Humar B. Oligonucleotide array outperforms SNP array on formalin-fixed paraffin-embedded clinical samples. *Cancer Genetics and Cytogenetics* 2010; **198**: 1-6

11. Kemp RA , Yoon H-S , Anjomshoaa A , Reeve AR. Using T Cell Responses In The Lymph Node To Predict Patient Outcome In Colorectal Cancer. *The Journal of Immunology* 2009;**182**: Supplement\_1
12. Zou D, Yoon HS, Anjomshoaa A, Perez D, Fukuzawa R, Guilford P, Humar B. Increased levels of active c-Src distinguish invasive from in situ lobular lesions. *Breast Cancer research* 2009; **11**(4): R45
13. Anjomshoaa A, Nasri S, Humar B, McCall JL, Chatterjee A, Yoon HS, McNoe L, Black MA, Reeve AE. Slow proliferation as a biological feature of colorectal cancer metastasis. *British Journal of Cancer* 2009; **101**: 822-828
14. Anjomshoaa A, Lin YH, Black MA, McCall JL, Humar B, Song S, Fukuzawa R, Yoon HS, Holzmann B, Friederichs J, van Rij A, Thompson-Fawcett M, Reeve AE. Reduced expression of a gene proliferation signature is associated with poor outcome in colorectal cancer. *British Journal of Cancer* 2008; **99**: 966-973
15. Lin HM, Chatterjee A, Lin YH, Anjomshoaa A, Fukuzawa R, McCall JL, Reeve AE. Genome wide expression profiling identifies genes associated with colorectal liver metastasis. *Oncology Reports* 2007; **17**: 1541-9
16. Anjomshoaa A, Lin Y-H, Black MA, McCall J, Reeve A.E. Poor outcome in colorectal cancer patients harboring reduced expression of a multi-gene proliferation signature. *Annals of Oncology* 2007; **18**: Conference Paper
17. Abstracts of the 2007 World Congress on Gastrointestinal Cancer, 28 June-1 July, 2007, Barcelona, Spain. *Annals of Oncology* 2007 June
18. Ehsan M, Abroon S, Anjomshoaa A, RezaPour M, Rezaie Z. Allelic frequency of HLA A, B and DR in AML patients in Kerman province. *The Scientific Journal of Iranian Blood Transfusion Organization* 1394, **12**, 233-243

